The Chinse drug administration approved Chongqing Lummy Pharmaceutical's (SHE:300006) supplementary application for alanyl glutamine injection's two specifications, according to a Shenzhen Stock Exchange disclosure on Tuesday.
The approval covers 50 milliliters: 10 grams and 100ml:20g.
The drug is suitable for parenteral nutrition of patients who need glutamine supplementation, including those with catabolic and hypermetabolic conditions, the pharmaceutical company said.
Lummy's shares jumped more than 8% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.